Kanaph Therapeutics focuses on global technology transfers and clinical data; "We will overcome our weaknesses"
Predicted impact: Low
General IR and technology-transfer messaging; no new contract size or financial figures.
Kanaph Therapeutics카나프테라퓨틱스
0082N0 · KOSDAQ · ₩0082N0 · 카나프테라퓨틱스
₩9,810▼ ₩20 (0.20%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −80.61%
- Market cap
- ₩130B
- Enterprise value
- ₩85B
- P/E
- —
- P/B
- 2.8×
- Dividend yield
- 0.0%
- ROE
- −76.8%
- Net margin
- −639.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−86.0% from the high
₩9,170Today: ₩9,670 – ₩10,380₩70,000
Returns
- 1W−6.9%
- 1M−18.1%
- 3M−11.3%
- 6M−74.2%
- YTD−80.6%
- 1Y—
- Volume today
- 77,558
- 0.6× the 20-day average
- Traded today
- ₩775M
- Listed shares
- 13,300,580
- EPS (12 months)
- −₩2,674
- Earnings yield −27.3%
AI research · InitiationKanaph Therapeutics: Loss-making KOSDAQ biotech trades far below its 52-week high after a 2026 listingThe data shows a recently listed biotech with a clean balance sheet but persistent losses, negative free cash flow and a share price that has fallen sharply from its high.Read the full report →IPOListed Mar 16, 2026 at ₩20,000IPO details →
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only one headline is available, and it reads as neutral. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-17.7% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Kanaph Therapeutics stock overview
Kanaph Therapeutics (카나프테라퓨틱스, KRX: 0082N0) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean innovative drug developer that uses human genome-based drug discovery technology to develop anticancer and ophthalmic disease therapies. Its shares closed at ₩9,810 on Oct 27, 2026, down 0.20% on the day, giving it a market value of ₩130B.
Key facts
- Market cap
- ₩130B
- Sector
- Biotech & Pharma
- Latest price change
- −0.20%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean innovative drug developer that uses human genome-based drug discovery technology to develop anticancer and ophthalmic disease therapies.
Quick answers about Kanaph Therapeutics
- What does Kanaph Therapeutics do?
- The company is a Korean innovative drug developer that uses human genome-based drug discovery technology to develop anticancer and ophthalmic disease therapies. Its pipeline spans bispecific antibodies, antibody-drug conjugates (ADCs), and small-molecule synthetic drugs, and it focuses on early-stage research through clinical early phases. It primarily generates revenue through early technology transfers and joint development deals with domestic and global pharmaceutical companies.
- What is the market cap of Kanaph Therapeutics?
- The market capitalisation of Kanaph Therapeutics was ₩130B at the close on Oct 27, 2026.
- Who are the largest shareholders of Kanaph Therapeutics?
- According to the latest official filings, the largest reported holders are LEE BYOUNG CHUL (36.04%, as of Sep 18, 2026); GC Pharma (10.99%, as of Mar 17, 2026); Solidus Investment (5.81%, as of Mar 23, 2026).
- When is the next earnings report from Kanaph Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when Kanaph Therapeutics filed the same report in past years, its next annual results is expected around Mar 19, 2027.
Company profile
The company is a Korean innovative drug developer that uses human genome-based drug discovery technology to develop anticancer and ophthalmic disease therapies. Its pipeline spans bispecific antibodies, antibody-drug conjugates (ADCs), and small-molecule synthetic drugs, and it focuses on early-stage research through clinical early phases. It primarily generates revenue through early technology transfers and joint development deals with domestic and global pharmaceutical companies.
Written by AI from the company's latest annual report.
- Korean name
- 카나프테라퓨틱스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이병철
- Founded
- Feb 2019
- Listed
- Mar 2026
- Listed shares
- 13,300,580
- Fiscal year ends
- Month 12
- Website
- www.kanaphtx.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
[Today's IR] Hyundai Rotem, Allixpharma, Canaphytetherapeutics and Others
Predicted impact: Low
Canopy Therapeutics: 'Bispecific antibody ADC shows excellent anti-tumor efficacy and tolerability'
Predicted impact: Low· Actual: −3.3% vs sector, volume 4.3× normal (5 trading days)
Same ADC anti-tumor efficacy data already reported in the last 14 days; no new size.
Recent filings
See all- Notice on Grant of Stock Purchase OptionsOct 22, 2026
- Investor relations (IR) eventOct 12, 2026
- 5%+ holding reportSep 18, 2026
- Investor relations (IR) eventSep 8, 2026
- Half-year report (Jun 2026)Aug 12, 2026
Titles in Korean until English translations are added.
Also known as: Kanaph Therapeutics / 카나프테라퓨틱스 / 0082N0 / KRX:0082N0
Source: KRX statistical information